Cargando…

Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas

BACKGROUND: S-phase kinase-associated protein 2 (Skp2) is a member of mammalian F-box proteins. The purpose of this study is to clarify the prognostic significance of expression of Skp2 related to gender, estrogen receptor (ER) and progesterone receptor (PGR) in soft tissue sarcomas (STS). Skp2 has...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorbye, Sveinung W, Kilvaer, Thomas K, Valkov, Andrej, Donnem, Tom, Smeland, Eivind, Al-Shibli, Khalid, Bremnes, Roy M, Busund, Lill-Tove
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602168/
https://www.ncbi.nlm.nih.gov/pubmed/23497154
http://dx.doi.org/10.1186/1472-6890-13-9
_version_ 1782263543182131200
author Sorbye, Sveinung W
Kilvaer, Thomas K
Valkov, Andrej
Donnem, Tom
Smeland, Eivind
Al-Shibli, Khalid
Bremnes, Roy M
Busund, Lill-Tove
author_facet Sorbye, Sveinung W
Kilvaer, Thomas K
Valkov, Andrej
Donnem, Tom
Smeland, Eivind
Al-Shibli, Khalid
Bremnes, Roy M
Busund, Lill-Tove
author_sort Sorbye, Sveinung W
collection PubMed
description BACKGROUND: S-phase kinase-associated protein 2 (Skp2) is a member of mammalian F-box proteins. The purpose of this study is to clarify the prognostic significance of expression of Skp2 related to gender, estrogen receptor (ER) and progesterone receptor (PGR) in soft tissue sarcomas (STS). Skp2 has been demonstrated to display an oncogenic function since its overexpression has been observed in many human cancers. Optimized treatment of STS requires better identification of high-risk patients who will benefit from adjuvant therapy. The prognostic significance of Skp2 related to ER and PGR in STS has not been sufficiently investigated. METHODS: Tissue microarrays from 193 STS patients were constructed from duplicate cores of viable and representative neoplastic tumor areas. Immunohistochemistry was used to evaluate the expression of Skp2, ER and PGR. RESULTS: In univariate analyses, high tumor expression of Skp2 correlated (p = 0.050) with reduced disease-specific survival (DSS). In subgroup analyses expression of PGR in males (p = 0.010) and in patients older than 60 years (p = 0.043) were negative prognostic factors for DSS. Expression of ER in females was a positive prognostic factor for DSS (p = 0.041). In co-expression analyses in the whole cohort, low expression of Skp2 in combination with low expression of ER was positive for DSS (p = 0.049). In females high expression of Skp2 in combination with low expression of ER was a negative prognosticator (p = 0.021). In the multivariate analyses, age (p = 0.012), malignancy grade (p < 0.001), wide resection margins (P = 0.010), ER negative / PGR positive co-expression profile (p = 0.002) and ER positive / PGR negative co-expression profile (p = 0.015) were independent negative prognostic factors for DSS. In females expression of Skp2 (p = 0.006) was associated with shorter DSS. CONCLUSIONS: We found diverse prognostic impacts of expression of Skp2, ER, PGR and DSS in male and female patients with STS. In men, but not women, ER positive / PGR negative co-expression profile was an independent negative prognostic factor for DSS. In women, but not men, high expression of Skp2 was associated with reduced DSS.
format Online
Article
Text
id pubmed-3602168
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36021682013-03-20 Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas Sorbye, Sveinung W Kilvaer, Thomas K Valkov, Andrej Donnem, Tom Smeland, Eivind Al-Shibli, Khalid Bremnes, Roy M Busund, Lill-Tove BMC Clin Pathol Research Article BACKGROUND: S-phase kinase-associated protein 2 (Skp2) is a member of mammalian F-box proteins. The purpose of this study is to clarify the prognostic significance of expression of Skp2 related to gender, estrogen receptor (ER) and progesterone receptor (PGR) in soft tissue sarcomas (STS). Skp2 has been demonstrated to display an oncogenic function since its overexpression has been observed in many human cancers. Optimized treatment of STS requires better identification of high-risk patients who will benefit from adjuvant therapy. The prognostic significance of Skp2 related to ER and PGR in STS has not been sufficiently investigated. METHODS: Tissue microarrays from 193 STS patients were constructed from duplicate cores of viable and representative neoplastic tumor areas. Immunohistochemistry was used to evaluate the expression of Skp2, ER and PGR. RESULTS: In univariate analyses, high tumor expression of Skp2 correlated (p = 0.050) with reduced disease-specific survival (DSS). In subgroup analyses expression of PGR in males (p = 0.010) and in patients older than 60 years (p = 0.043) were negative prognostic factors for DSS. Expression of ER in females was a positive prognostic factor for DSS (p = 0.041). In co-expression analyses in the whole cohort, low expression of Skp2 in combination with low expression of ER was positive for DSS (p = 0.049). In females high expression of Skp2 in combination with low expression of ER was a negative prognosticator (p = 0.021). In the multivariate analyses, age (p = 0.012), malignancy grade (p < 0.001), wide resection margins (P = 0.010), ER negative / PGR positive co-expression profile (p = 0.002) and ER positive / PGR negative co-expression profile (p = 0.015) were independent negative prognostic factors for DSS. In females expression of Skp2 (p = 0.006) was associated with shorter DSS. CONCLUSIONS: We found diverse prognostic impacts of expression of Skp2, ER, PGR and DSS in male and female patients with STS. In men, but not women, ER positive / PGR negative co-expression profile was an independent negative prognostic factor for DSS. In women, but not men, high expression of Skp2 was associated with reduced DSS. BioMed Central 2013-03-15 /pmc/articles/PMC3602168/ /pubmed/23497154 http://dx.doi.org/10.1186/1472-6890-13-9 Text en Copyright ©2013 Sorbye et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sorbye, Sveinung W
Kilvaer, Thomas K
Valkov, Andrej
Donnem, Tom
Smeland, Eivind
Al-Shibli, Khalid
Bremnes, Roy M
Busund, Lill-Tove
Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
title Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
title_full Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
title_fullStr Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
title_full_unstemmed Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
title_short Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
title_sort prognostic impact of skp2, er and pgr in male and female patients with soft tissue sarcomas
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602168/
https://www.ncbi.nlm.nih.gov/pubmed/23497154
http://dx.doi.org/10.1186/1472-6890-13-9
work_keys_str_mv AT sorbyesveinungw prognosticimpactofskp2erandpgrinmaleandfemalepatientswithsofttissuesarcomas
AT kilvaerthomask prognosticimpactofskp2erandpgrinmaleandfemalepatientswithsofttissuesarcomas
AT valkovandrej prognosticimpactofskp2erandpgrinmaleandfemalepatientswithsofttissuesarcomas
AT donnemtom prognosticimpactofskp2erandpgrinmaleandfemalepatientswithsofttissuesarcomas
AT smelandeivind prognosticimpactofskp2erandpgrinmaleandfemalepatientswithsofttissuesarcomas
AT alshiblikhalid prognosticimpactofskp2erandpgrinmaleandfemalepatientswithsofttissuesarcomas
AT bremnesroym prognosticimpactofskp2erandpgrinmaleandfemalepatientswithsofttissuesarcomas
AT busundlilltove prognosticimpactofskp2erandpgrinmaleandfemalepatientswithsofttissuesarcomas